Tissue Array Research Program and Applied Molecular Pathology Laboratory, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4605, USA.
Hum Pathol. 2013 Apr;44(4):472-9. doi: 10.1016/j.humpath.2012.06.018. Epub 2012 Oct 12.
Synaptonemal complex protein 3 is a marker for cell transformation that has prognostic significance in various cancers. However, the prognostic significance of synaptonemal complex protein 3 has not been studied in non-small cell lung cancer. To investigate the potential correlation between synaptonemal complex protein 3 and various clinicopathologic parameters, we assessed the expression of synaptonemal complex protein 3 in archival tumor tissues from 258 patients with non-small cell lung cancer by immunohistochemical staining. By immunofluorescence, synaptonemal complex protein 3 was detected in both the cytoplasmic and nuclear fractions of NCI-H1299 cell. In tumor samples, synaptonemal complex protein 3 is detected as cytoplasmic expression pattern and observed in 50 clinical samples (19.4%) by immunohistochemical staining. Synaptonemal complex protein 3 expression was correlated with T status (P = .008), lymph node metastasis (P = .010), tumor types (P = .019), and pleural invasion (P = .005). In multivariate analysis of patients with early stage disease, increased synaptonemal complex protein 3 expression predicted worse overall survival in early stage (stage I and II) with pT1 status (P = .041). These results suggest that positive synaptonemal complex protein 3 expression is a portent of poor outcome and may be a potential biomarker in the early stages of the non-small cell lung cancer for survival and may provide clues in the identification of patients for adjuvant therapy.
联会复合体蛋白 3 是一种细胞转化的标志物，在多种癌症中具有预后意义。然而，联会复合体蛋白 3 在非小细胞肺癌中的预后意义尚未得到研究。为了研究联会复合体蛋白 3 与各种临床病理参数之间的潜在相关性，我们通过免疫组织化学染色评估了 258 例非小细胞肺癌患者存档肿瘤组织中联会复合体蛋白 3 的表达。通过免疫荧光，在 NCI-H1299 细胞的细胞质和核部分均检测到联会复合体蛋白 3。在肿瘤样本中，通过免疫组织化学染色检测到联会复合体蛋白 3 呈细胞质表达模式，在 50 例临床样本（19.4%）中观察到。联会复合体蛋白 3 的表达与 T 状态（P=0.008）、淋巴结转移（P=0.010）、肿瘤类型（P=0.019）和胸膜侵犯（P=0.005）相关。在早期疾病患者的多变量分析中，联会复合体蛋白 3 表达增加预示着具有 pT1 状态的早期（I 期和 II 期）患者总体生存较差（P=0.041）。这些结果表明，联会复合体蛋白 3 阳性表达是预后不良的标志，可能是非小细胞肺癌早期生存的潜在生物标志物，并可能为辅助治疗患者的识别提供线索。
